Siltuximab

From WikiMD's Wellness Encyclopedia

(Redirected from CNTO 328)

What is Siltuximab?[edit | edit source]



What are the uses of this medicine?[edit | edit source]


How does this medicine work?[edit | edit source]

  • Siltuximab binds human IL-6 and prevents the binding of IL-6 to both soluble and membrane-bound IL-6 receptors.
  • IL-6 has been shown to be involved in diverse normal physiologic processes such as induction of immunoglobulin secretion.
  • Overproduction of IL-6 has been linked to systemic manifestations in patients with MCD.


Who Should Not Use this medicine ?[edit | edit source]

This medicine cannot be used in patients with:


What drug interactions can this medicine cause?[edit | edit source]

  • Cytochrome P450s in the liver are down regulated by infection and inflammation stimuli including cytokines such as IL-6. Inhibition of IL-6 signaling in patients treated with Sylvant may restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment with Sylvant.


Is this medicine FDA approved?[edit | edit source]

  • This medicine is approved in the year 2014.


How should this medicine be used?[edit | edit source]

Recommended Dosage:

  • Administer Sylvant 11 mg/kg over 1 hour as an intravenous infusion every 3 weeks until treatment failure.

Administration

  • Sylvant is given by an intravenous (IV) infusion into a vein over 1 hour.
  • Sylvant is given every 3 weeks.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form: As injection

  • 100 mg of lyophilized powder in a single-dose vial.
  • 400 mg of lyophilized powder in a single-dose vial.

This medicine is available in fallowing brand namesː

  • Sylvant


What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:

Sylvant may cause serious side effects, including:

  • Infections
  • Infusion and allergic reactions


What special precautions should I follow?[edit | edit source]

  • Do not administer Sylvant to patients with severe infections, monitor for infections, institute prompt treatment, and interrupt Sylvant until resolution of infection.
  • Do not administer live vaccines because IL-6 inhibition may interfere with the normal immune response to new antigens.
  • Sylvant may cause infusion related reactions and anaphylaxis. Administer Sylvant in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.
  • Gastrointestinal (GI) perforation has been reported in clinical trials. Promptly evaluate patients presenting with symptoms that may be associated or suggestive of GI perforation.


What to do in case of emergency/overdose?[edit | edit source]

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.


Can this medicine be used in pregnancy?[edit | edit source]

  • The limited available information on Sylvant use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage.


Can this medicine be used in children?[edit | edit source]

  • The safety and efficacy of Sylvant have not been established in pediatric patients.


What are the active and inactive ingredients in this medicine?[edit | edit source]

  • Active ingredient: siltuximab
  • Inactive ingredients: L-histidine and L-histidine monohydrochloride monohydrate, polysorbate 80, and sucrose


Who manufactures and distributes this medicine?[edit | edit source]

Manufactured by:


What should I know about storage and disposal of this medication?[edit | edit source]

  • Sylvant must be refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
  • Do not freeze.
  • Do not use Sylvant beyond the expiration date (EXP) located on the carton and the vial.
Siltuximab Resources


Contributors: Deepika vegiraju